Jefferies Upgrades AcelRx Pharmaceuticals (ACRX) to Buy

October 15, 2018 6:09 AM

Jefferies analyst Roger Song upgraded AcelRx Pharmaceuticals (NASDAQ: ACRX) from Hold to Buy with a price target of $8.00 (from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found